Vaginal Estrogen for UTI Prevention

Before 2014, doctors had a name for the cluster of symptoms that shows up in the vagina, vulva, and bladder after menopause: the senile vagina. Urologist Dr. Kelly Casperson still gets a laugh from clinicians when she says it out loud during talks (14:41). The term later softened to vulvovaginal atrophy, which was better but still missed something. At a 2014 consensus conference, urologist Dr. Irwin Goldstein pushed the group to add one more word: urinary. The condition does not stop at the vagina. It also drives urinary tract infections, urgency, and leakage. The result was genitourinary syndrome of menopause, or GSM (14:09).

That renaming matters because it changes what a doctor sees walking through the door. A 78 year old with bladder urgency, occasional infections, and pain during sex used to look like three separate problems, each with its own specialist and its own prescription pad. Casperson argues she is one problem with one cause: falling estrogen and testosterone thin and dry out the tissue that lines the vagina, vulva, urethra, and bladder neck (13:42). Fix the hormone deficiency, and all three symptoms tend to improve together. GSM, by her account, affects somewhere between 50 and 90 percent of women at menopause or after (17:27), which makes it one of the most common and least discussed conditions in medicine.

Casperson calls the myths that keep treatment rates low zombie myths, a phrase she credits to physician Dr. Jim Simon (10:54): ideas that should be dead but keep shambling back into exam rooms. The biggest one is that a history of breast cancer rules out vaginal hormones. It does not. A meta-analysis covering more than 50,000 women years of data found vaginal estrogen safe in women with a history of the disease (11:16). The American College of Obstetricians and Gynecologists said as much in a 2016 committee opinion, and in 2025 the American Society of Clinical Oncology's annual meeting reported that local estrogen does not reduce survival among breast cancer patients (60:06). Casperson sounds almost tired repeating it: we have been saying it is safe for over a decade, and the doubt keeps returning anyway (60:29).

What the UTI Data Actually Show

The strongest new evidence in the episode concerns urinary tract infections. Vaginal estrogen is topical, meaning it acts locally and does not circulate through the bloodstream the way a pill or patch does. A database study out of Stanford, led by a researcher Casperson calls Dr. Day, compared women with recurrent UTIs who used vaginal estrogen against those who did not (18:26). Recurrent UTI has a specific medical definition: two infections in six months, or three in a year (21:05). The women on vaginal estrogen had lower risk not just of another infection, but of hospitalization, ICU admission, and death.

"Women on vaginal estrogen, statistically significant decreased risk of death, admission to the hospital, admission to the ICU, and sepsis death." (Dr. Kelly Casperson, [19:32])

The likely mechanism: estrogen keeps the tissue of the urethra and vaginal wall thick and well supplied with blood, and it supports a healthy vaginal microbiome that can crowd out the bacteria responsible for UTIs. Antibiotics, ironically, can wipe out that microbiome, which is one reason Casperson thinks vaginal estrogen may help even younger, premenopausal women who get repeat infections after a course of antibiotics (19:32). The Stanford data showed a benefit down to age 20, which suggests the mechanism is not limited to menopause itself.

Despite all this, treatment is rare. A separate Medicare database study, also from Stanford and also published at the end of 2025, followed women 65 and older who had already cleared two hurdles: they saw a doctor, and they received a correct diagnosis of GSM. Of that group, only 9 percent received a prescription for vaginal estrogen (20:32). Part of the problem is cost confusion. Generic estradiol cream runs about $14 a month at Cost Plus Drugs, the online pharmacy founded by Mark Cuban (22:21), while some patients report paying $100 to $250 for brand name Premarin, which is owned by Pfizer and has no US generic (27:49). Part of the problem is silence: Casperson cites data showing the average woman waits seven to eight years before telling a doctor about bladder leakage, and she suspects the wait is just as long, or longer, for pain during sex (12:51).

Choosing and Using the Right Product

Not every vaginal hormone product is identical. Estradiol, the generic cream widely available in the US, is chemically identical to the estrogen the body makes. Premarin is a mix of conjugated equine estrogens, extracted from the urine of pregnant mares (27:26). In Europe, the more common option is estriol, a weaker form of estrogen with its own body of published research. Casperson says head to head trials comparing all three do not exist, but her working assumption is that all three are likely equivalent, and all beat doing nothing (27:26).

Application matters as much as the product. Casperson recommends a loading dose, applied nightly for the first two weeks, to rebuild atrophied tissue, then a maintenance schedule of twice a week (39:20). She is clear that twice a week is a maintenance dose, not a treatment dose. Some patients need more, and reverting to a heavier schedule when symptoms return is common and appropriate (56:04). Cream can go on with a finger instead of the applicator, and can be applied to the vulva as well as inside the vagina, since the labia and clitoris are also hormone sensitive tissue that can lose volume and function without estrogen and testosterone (26:03).

For deeper atrophy, Casperson turns to vaginal DHEA, sold in the US as Intrarosa (prasterone). Unlike estradiol, DHEA converts locally, inside pelvic tissue, into both testosterone and estrogen (61:45), which is why she considers it more effective for reversing atrophy that has already set in, rather than simply preventing it (30:33). The catch is price: in Australia, where Casperson recently spoke at the Sydney Opera House, insurance covers the drug for about $40 a month, while in the US the same medication costs roughly $80 a month with insurance and up to $300 without it (59:18). For patients who cannot manage a twice weekly cream, whether from arthritis, memory loss, or limited mobility, she recommends two alternatives: an oral pill called Osphena (ospemifene), or a vaginal ring that only needs changing every three months (58:06).

Casperson is direct about where caution is real and where it is not. Local vaginal hormones, she says, do not enter the bloodstream in meaningful amounts, which is why they are considered safe for patients on dialysis (40:42), why they do not affect bone density (47:36), and why they no longer carry the warning that still scares people. The FDA boxed warning linking vaginal estrogen to blood clots, stroke, and cancer was removed after more than a decade of advocacy, because the underlying data never supported it for local, low dose products (60:54). Genuine caution belongs elsewhere: a history of blood clots or pulmonary embolism warrants a specialist visit before starting any hormone therapy (50:04), while dense breasts or a family history of breast cancer are not, on their own, reasons to withhold treatment (51:20).

She is most pointed about a different gap in care: the roughly 5 percent of women who have their ovaries removed for benign reasons, not cancer, who are actually offered hormone therapy afterward, according to research from UK menopause specialist Dr. Louise Newson's group (44:25). Casperson, who as a urologist removes testicles for cancer, makes the comparison explicit.

"If a urologist ever removed testicles and did not replace testosterone in a man, that's malpractice. Use that information how you will." (Dr. Kelly Casperson, [44:25])

That line captures the whole argument. GSM is not a mystery condition waiting on more research. It has a defined name, a known cause, cheap and well studied treatments, and, by Casperson's account, more than a decade of safety data even in breast cancer survivors. What is missing is not evidence. It is the plumbing that gets evidence from a study to a prescription pad, and from a prescription pad to a patient who has spent years assuming her symptoms are simply what happens after fifty.